Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maprotiline in pain-depression.

P G Lindsay, R B Olsen

    The Journal of Clinical Psychiatry
    |June 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Maprotiline, a second-generation antidepressant, effectively reduced chronic pain by over 50% in 72% of patients. This study suggests maprotiline

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Social networks and longevity. A 14 year follow-up study among elderly in Denmark.

    Social science & medicine (1982)·1991
    Same author

    Psychotropic medication in the elderly. A survey of prescribing and clinical outcome.

    Danish medical bulletin·1990
    Same author

    [Consumption of psychopharmaceuticals by residents at nursing homes. Significance of the environment at the nursing home].

    Ugeskrift for laeger·1989
    Same author

    Neuropeptides: ACTH-peptides in dementia.

    Progress in neuro-psychopharmacology & biological psychiatry·1986
    Same author

    Depression of essential tremor by alpha-adrenergic blockade.

    Journal of neurology, neurosurgery, and psychiatry·1981
    Same author

    The depression-pain syndrome and its response to antidepressants.

    Psychosomatics·1981
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Pain Management
    • Neurology

    Background:

    • Chronic pain affects millions globally, necessitating effective treatment options.
    • Second-generation antidepressants are increasingly explored for pain management.
    • Maprotiline's efficacy in chronic pain requires further investigation.

    Purpose of the Study:

    • To evaluate the effectiveness of maprotiline in treating chronic pain.
    • To determine the response rate of chronic pain patients to maprotiline therapy.

    Main Methods:

    • A cohort of 25 patients with chronic pain was treated with maprotiline.
    • Pain reduction was assessed by a greater than 50% decrease in the pain syndrome.

    Main Results:

    Related Experiment Videos

  • 18 out of 25 patients (72%) experienced a significant reduction in chronic pain.
  • Maprotiline demonstrated comparable effectiveness to earlier antidepressant treatments for pain.

    • Conclusions:

    • Maprotiline is an effective second-generation antidepressant for managing chronic pain.
    • The enkephalin induction hypothesis may explain the mechanism of action for antidepressants in pain relief.